Member Info for 1DayRodney

What a numpty thing to post.

How 'bout you tell us your research for such a bold and definitive statement?

Next you'll be saying 'nudge, nudge, wink, wink...say no more..' 🙄

@EmCarrot

'For the 14 Hospital trial, then we wait for the NICE rollout decision early July.'

Is that decision not until 2027?

"Funding for PALOH-UK sites is provided by the Office for Life Sciences ("OLS") and National Institute for Health and Care Research ("NIHR") and will cease by June 2026, with some sites completing earlier. Subsequent review and issuance of final guidance by NICE is expected around July 2027."

Which is an absolutely ridiculous timescale - so much for NICE 'fastrack' 🤨

However, Gino stated in the same RNS (referring to Sussex hospital continued uptake).

"We are in active discussions with other hospitals in the PALOH-UK programme to support the transition of our MT-RNR1 test from PALOH-UK based funding to embedding into routine practice to ensure that newborn babies across the UK continue to have access to this preventive test."

So hopefully we're going to get at least some continuance of business from those other hospitals already in the study.

The problem we don't know what the current figures are!

• Assets (including IP and patents) - 🤷‍♂️

• Turnover - £? will find out in Dec

• Potential - 🔮... somewhere between 'sky's the limit' and 🪦. Unfortunately the 'potential' is also very much in the hands of NICE and FDA.

At the moment, I think the price and it's controlled growth are about right. For me personally, I would like to think that I could make acceptable profit here one day and for the Genedrive product to continue to thrive in one form or another.

@Amers

You've been bandying the '10p within 12mths' figure around for a while now.

What's your reasoning/evidence for this or are you really Septic Peg?

https://youtu.be/s6kCSsfp_Tk?si=dVZgh469GUHgD9KZ

🔮

Fingers crossed the new non-exec chair and directors search is a swift and fruitful one.

Hopefully one will be sales orientated. We really need a fresh and concentrated drive towards substantial revenue and make a profit.

We should aim to be rapidly moving towards a point where any future raise are small and for product/assay expansion, not just to keep the lights on💡!

Despite certain posters' obvious shenanigans and ramping here, I believe the SP here will climb slowly but steadily with the odd boost on sales or qualification news.

~~~~~~~~

After all, I myself am looking forward to top-slicing when we hit 15p this time next year, while continuing to hold the balance for the 30p buyout shortly after (💭😉).

My source..

https://www.dictionary.com/browse/ironic

Didn't think Gino was going anywhere and was still CEO with Russ still CFO...

"I am excited to be joining the Board and working with Gino and Russ as the Company drives adoption and executes its commercial strategy in the UK and internationally."

or have I misunderstood your comment BigH ?🤔

Fingers crossed we can make firm progress towards production and maybe get some capital flowing in with the existing assets before we get diluted further with another site purchase.

In my mind, we've got to to prove Molly & Para are profitable to increase confidence all round, demonstrating that the company's research and purchase process can be trusted and that the company is investable.

GLA

Great watching this creep up to the 800 milestone.

It'll be interesting to see if it climbs much higher above the mark, and maintain it, as we creep towards the end of year merger with its associated capital cost and 18% share dilution.

Seems the market believes it's the right move...

Nissangtr786 wrote "That could mean 3p could be very close with news due next month."

You won't be here then anyways nissan - thought you were selling when it reached 2.3p! 😆

Lionel said

"The test NUH (Nottingham) is using is Genomadix CUBE. I’m curious why they chose Genomadix over Genedrive, it seems like a strange decision, that’s why we have not seen any RNS or press release from Genedrive ."

In my deep, dark memory, I believe there was a previously posted link of Teams YouTube video in which there was a discussion between several hospital depts/users about this POC test. One of the attendees said that Genomadix offered a free/subsidised trial for their product but Genedrive didn't offer the same, so the hospital had gone with them instead.

Don't quote me on it, and things may have changed, but that could be a reason.

Need the get this bl@@dy red tape torture out of the way! There must be so many innovative companies out there with diamond products, but they just hit the test/procurement wall and fade away due to running out money - absolutely criminal.

GLA

"Even 2.3p I would take now"

God dammit! Stop ya whining a make like you've got a pair!

Your many, many, many, many, many "I'd sell for xx" prices over the many, many months have been and gone many, many, (you get the idea..) times.

JUST SELL UP NOW and invest in Space X or something!!

😉

BOD still 'Bullish' - todays X post

"Rising bond yields are pressuring gold prices in the short term but we believe this is likely a cyclical phase, not a structural shift. Inflation risks, geopolitical uncertainty, and central bank buying still provide strong long-term support for gold. We remain bullish about our gold strategy and as reported in last announcement, await full results from Molly Gold Project drilling programme. #gold #mining #goldequities"

🤞the Molly results are 🎇 and not 💩 - would be nice to stop the creeping price drop and move up a step or two!

The lab 'preference' recommendation was only for the CYP219 stroke test not the MT-RNR1 hearing antibiotic test.

Further, if you read the RNS from 13th Feb you will see that GDR will be developing a new lab version of the CYP219 test to cover both lab and POC scenarios.

@smalleyus

Re RNS 13March

"We are now planning the next phase of drilling at TP2 and TP3.2 while continuing to advance and develop additional exploration targets within Paranaíta. We are also working to deliver an enhanced geological model, with the aim of expanding the initial inferred mineral resource of 210,000 oz Au, reporting it to JORC standards."

So I guess we're still test drilling....👷‍♂️🔨

@MT100

You can read 'from the horse's mouth' so to speak.

His last comment (user NUG1) is on this bulletin board & can found dated 16th March under the title 'Clarity'.

The 2.6% represents the increase in the dividend not it's value.

The dividend works out at about 8.3%

IMHO, these recent concerns and thoughts about the moral standings and future intentions of some of our major shareholders is just an unwanted and pointless distraction at this juncture!

ALL shareholders priority should now be concentrating on the BOD and and keeping on it's case to ensure it keeps to the timetable and mandate stated in the offer publication!

This company needs to be self-sustainable and then profitable in quick short time otherwise it'll just wither away into administration despite the excellent science and products.

The company has just raised a lot of cash, so, I think it extremely doubtful anything is going to happen anytime soon with the company's structure (unless a golden giant pharma egg drops in our lap of course!).

No more false hopes and excuses. The shareholders and institutional investors have shown their support (again!) and it's time for the company to reciprocate, BIG TIME!

GLA

@VikR

Should we be expecting a TR-1 soon? 😉

Fully funded and fully certified (UK) unique life changing products.

This should and needs to be at 5p before FDA application(s) even start.

Science/Technology - 5*

Testing and proof of application - 5*

Now commercial sales needs to match and hit 5* too 👊!